Compare NOMA & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMA | KYNB |
|---|---|---|
| Founded | 2023 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 32.8M |
| IPO Year | 2025 | 2014 |
| Metric | NOMA | KYNB |
|---|---|---|
| Price | $1.78 | $6.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 24.3K |
| Earning Date | 05-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9552.08 |
| EPS | ★ N/A | N/A |
| Revenue | $6,376.00 | ★ $6,440,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $6.32 |
| 52 Week High | $10.00 | $9.58 |
| Indicator | NOMA | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 32.62 |
| Support Level | $1.31 | $6.74 |
| Resistance Level | $2.47 | $7.47 |
| Average True Range (ATR) | 0.21 | 0.41 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 81.31 | 4.83 |
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.